Oct. 15 to Oct. 17, 2024: Colorado Free Application Days

Submit your application to CU Denver between Oct. 15 and 17 and your $50 application fee will be waived.

Learn More

Meet our SPARK Fellows

Development of Gated Dual-antigen Targeting CAR-T Cell Therapy to Treat ATRT, an Aggressive Brain Tumor in Children

This project aims to address the high unmet needs in atypical teratoid/rhabdoid tumor (ATRT) which is a highly aggressive childhood brain tumor with a 5-year survival rate of 35%. Current treatments, including intensive chemotherapy, radiation, and stem cell transplants, result in significant toxicity and poor outcomes. The loss of the SMARCB1 gene, leading to epigenetic dysregulation, is a key feature of ATRT. Targeting SMARCB1 loss has been challenging, necessitating new therapies. ATRT cells uniquely express high levels of B7-H3 and EphA2 antigens. To avoid off-target toxicities, the team proposes developing CAR T cells that recognize both antigens using a bicistronic CAR construct with Boolean logic “AND” rules, ensuring specificity to ATRT cells while protecting normal tissues. Collaborators: Sujatha Venkataraman, PhD and Rajeev Vibhakar, MD, PhD, MPH/MSPH

Learn more about Dr. Venkataraman

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-6653

CMS Login